[Recent development of anticoagulation in stroke prevention for atrial fibrillation].
Anticoagulants are recommended for preventing stroke in patients with non-valvular atrial fibrillation (NVAF). Warfarin has been the most common oral anticoagulant for several decades, but use of warfarin has many limitations. Recently, several novel anticoagulants that can overcome the limitations of warfarin have been developed, and some of them are already used in clinical practice in Japan. In this review, we overview the pharmacological mechanisms and the results of the phase III trial of the novel anticoagulants for preventing stroke in patients with NVAF based on the comparison to warfarin.